AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS
AND AMERICAN COLLEGE OF ENDOCRINOLOGY
POSITION STATEMENT ON THE ASSOCIATION OF
SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS

This document represents the official position of the American Association of Clinical Endocrinologists and American College of Endocrinology. Where there were no randomized controlled trials or specific U.S. FDA labeling for issues in clinical practice, the participating clinical experts utilized their judgment and experience. Every effort was made to achieve consensus among the committee members. Position statements are meant to provide guidance, but they are not to be considered prescriptive for any individual patient and cannot replace the judgment of a clinician.
EXECUTIVE SUMMARY

Recent reports of diabetic ketoacidosis (DKA) occurring in conjunction with sodium glucose-cotransporter 2 (SGLT-2) inhibitor therapy have raised concerns that these agents may increase the risk of DKA, especially among patients taking exogenous insulin. On May 15, 2015, the U.S. Food and Drug Administration (FDA) issued the following safety communication concerning 20 cases of acidosis in patients taking SGLT-2 inhibitors reported to the FDA Adverse Event Reporting System (1):

“We are continuing to investigate this safety issue and will determine whether changes are needed in the prescribing information for...SGLT-2 inhibitors...Health care professionals should evaluate for the presence of acidosis, including ketoacidosis, in patients experiencing [DKA] signs or symptoms; discontinue SGLT-2 inhibitors if acidosis is confirmed; and take appropriate measures to correct the acidosis and monitor sugar levels.”

To address these concerns, the American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology (ACE) convened a public conference in which experts from Europe and the United States evaluated relevant cases and clinical data (see Appendix for agenda and participants). A detailed report on the scientific evidence for the association of SGLT-2 inhibitors with DKA follows this statement.

The key points described in this document are as follows:

1. For individuals with type 2 diabetes (T2D), it is unclear whether DKA occurs at a higher frequency than it did before the advent of SGLT-2 inhibitors. In 2010 in the United States, 142,000 hospitalizations were associated with DKA, 23% of which occurred in patients with T2D (2). In Denmark, the rate of DKA before the SGLT-2 inhibitor era was 1 to 2 cases per 1,000 patients with diabetes. The incidence of DKA in clinical trials of SGLT-2 inhibitors with T2D was 0.2 to 0.8 cases per 1,000 patient-years (3,4). However, the low observed incidence in clinical trials may not reflect real-world experience. Seemingly, most of the reported cases have come from clinical practice rather than trials. Patients with type 1 diabetes (T1D) have a higher risk of DKA than those with T2D, and their risk of developing DKA while taking SGLT-2 inhibitors should be further elevated. Up to 9.4% of patients with T1D participating in SGLT-2 inhibitor clinical trials developed ketosis, and up to 6% experienced DKA (5,6).

2. However, more data are needed to elucidate this relationship, as many recently reported cases have been poorly documented. Not all cases may have been actual DKA but rather ketosis (build-up of ketones)—which is not necessarily harmful—perhaps resulting from an earlier shift to fat metabolism potentially impacted by a mechanism related to SGLT-2 inhibition.

3. The majority of cases of SGLT-2 inhibitor-associated DKA have occurred in individuals with diabetes who are insulin deficient, such as those with latent autoimmune diabetes in adults (LADA) and T1D, but cases have also occurred in some patients with long-standing T1D. Generally, these patients presented with classical DKA signs and symptoms. However, some cases had an atypical presentation with a lower-than-expected degree of hyperglycemia. Lower-than-expected hyperglycemia, however, was observed with other agents years before the introduction of SGLT-2 inhibitors (7,8).

4. Precipitants of DKA in T1D and T2D include surgery, extensive exercise, myocardial infarction, stroke, severe infections, prolonged fasting, and other stressful physical and medical conditions; almost all cases of SGLT-2 inhibitor-associated DKA occurred in patients challenged with metabolically stressful events. In both T1D and T2D, diabetes-associated metabolic changes commonly shift substrate metabolism from carbohydrate to fat oxidation, thereby predisposing patients to more readily develop ketonemia and DKA during SGLT-2 inhibitor use.

5. For patients taking an SGLT-2 inhibitor who present with symptoms suggestive of DKA, such as abdominal pain, nausea, vomiting, fatigue, and dyspnea, a diagnosis of DKA should be considered and appropriate work-up carried out. Although a low bicarbonate and/or the presence of positive urinary ketones may be suggestive of DKA, these measures may be inaccurate. Therefore, AACE/ACE recommends direct measurement of blood ketones (β-hydroxybutyrate) and arterial pH as necessary to confirm the diagnosis. Normal or modestly elevated blood glucose does not exclude the diagnosis of DKA during SGLT-2 inhibitor use.

6. For management of DKA in patients taking SGLT-2 inhibitors, stop the drug immediately and proceed with traditional DKA treatment protocols. Note that although the drug is discontinued, SGLT-2 inhibitor–mediated increases in urinary glucose loss may persist for several days.

7. To minimize the risk of DKA associated with SGLT-2 inhibitors, AACE recommends the following:
Review of available data on the prevalence of SGLT-2–associated DKA as well as the impact of SGLT-2 inhibitors on human metabolism suggests that DKA occurs infrequently and that the risk-benefit ratio overwhelmingly favors continued use of SGLT-2 inhibitors with no changes in current recommendations. However, DKA diagnosis may be missed or delayed due to atypical presentation involving lower-than-anticipated glucose levels or other misleading laboratory values. This presentation has been seen with SGLT-2 inhibitors but has also been observed for decades before the introduction of these agents (9). Gaps in understanding call for more studies of the mechanisms behind the metabolic effect of SGLT-2 inhibitors as well as more healthcare professional education focused on the proper diagnosis and treatment of DKA. (Endocr Pract. 2016;22:xxx-xxx)

INTRODUCTION

Diabetic ketoacidosis (DKA) is an acute, potentially fatal complication of diabetes that typically occurs when insulin deficiency results in excessive lipolysis and protein breakdown at the tissue level, with increased hepatic beta-oxidation of fatty acids to ketone bodies, leading to ketoacidemia and metabolic acidosis (8). Sodium glucose-cotransporter 2 (SGLT-2) inhibitors are a class of antihyperglycemic agents that reduce blood glucose levels by blocking glucose re-absorption in the proximal tubule of the kidney, causing glycosuria (10). Reports of DKA occurring with SGLT-2 inhibitor therapy in patients with diabetes prompted a U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) safety communication (1,11). In October 2015, the American Association of Clinical Endocrinologists (AACE)/American College of Endocrinology (ACE) convened a conference of experts from Europe and the United States to evaluate reported cases, critically assess the scientific evidence for the association of SGLT-2 inhibitor therapy with DKA, and provide recommendations for the care of affected patients (see Appendix for agenda and participants). This position statement describes the findings of the conference and also represents the official position of AACE and ACE on DKA associated with SGLT-2 inhibitor use.

DOES DKA OCCUR AT A HIGHER RATE WITH SGLT-2 INHIBITORS THAN WITH OTHER ANTIHYPERGLYCEMIC MEDICATIONS?

Whether DKA currently occurs at a higher frequency than before the introduction of SGLT-2 inhibitors remains unclear. The Centers for Disease Control and Prevention estimated that the rate of DKA was 7.1 per 1,000 patient-years with diabetes in 2009, and in 2010, DKA accounted for 142,000 hospitalizations in the U.S., 33,000 of which involved patients with type 2 diabetes (T2D) (2,12). In an analysis of 4 large U.S.-based commercial claims databases, the incidence of DKA ranged between 0.32 and 2.0 per 1,000 patient-years (3). In Denmark, the rate of DKA between 2005 and 2012 ranged between 1.4 and 2.2 DKA events per 1,000 patient-years, and the overall rate
during that period was 1.8 events per 1,000 patient-years (J. Nolan, FRCP, FRCP[ED], data presented at consensus meeting). Between 1997 and 2000 in Sweden, the overall incidence of DKA was 1.5 per 1,000 patient-years; 32% of cases occurred in T2D patients, with an incidence of 0.5 per 1,000 patient-years (13).

Postmarketing reports of SGLT-2 inhibitor–associated acidosis (including DKA, ketoacidosis, and ketosis) include 20 cases reported to the FDA Adverse Event Reporting System through June 2015 and 147 cases in the EudraVigilance database (96 with canagliflozin, 46 with dapagliflozin, and 5 with empagliflozin) (1,14). In clinical trials with SGLT-2 inhibitors, DKA rates ranged between 0.2 to 0.8 cases per 1,000 patient-years among T2D patients (3,4). Canagliflozin received approval from U.S. and European agencies in 2013. In clinical trials with this agent, DKA and related events were reported in 12 of 17,596 study participants with T2D (0.07%). Canagliflozin 100 and 300 mg were associated with 4 and 6 DKA cases, respectively, whereas 2 events occurred in patients receiving a comparator. The corresponding incidence rates were 0.52, 0.76, and 0.24 per 1,000 patient-years, respectively (3). Empagliflozin received marketing approval in 2014, and data from both clinical and outcomes trials are available. Among 7,020 patients participating in the EMPA-REG OUTCOME trial, 5 DKA cases occurred over a median of 3 years, at a rate of 0.5 per 1,000 patient-years with empagliflozin 10 mg (3 cases) and 0.2 per 1,000 patient-years with empagliflozin 25 mg and placebo (1 case each) (4). In a retrospective analysis of randomized phase 2 and 3 empagliflozin trials (>13,000 T2D participants, including >8,000 patients treated with empagliflozin), there were 8 events consistent with DKA: 2 events with empagliflozin 10 mg, 1 event with empagliflozin 25 mg, and 5 events with placebo. The corresponding DKA event rates were 0.5 and 0.2 per 1,000 patient-years with empagliflozin 10 and 25 mg, respectively, whereas 1.2 events per 1,000 patient-years occurred among placebo-treated patients (T. Seck, MD, data presented at consensus meeting). Dapagliflozin gained European approval in 2012 and U.S. approval in 2014. In the phase 2b/3 dapagliflozin clinical development program (21 studies), 1 case of DKA was reported among the 5,936 dapagliflozin-treated patients (6,247.2 patient-years), or 0.015 per 1,000 patient-years (N. Iqbal, MD, MSCE, FACE, data presented at consensus meeting).

Patients with type 1 diabetes (T1D) have a higher risk of DKA than those with T2D (15,16). The total incidence of DKA in patients with T1D treated with SGLT-2 inhibitors is impossible to determine at this stage, although in clinical trials, up to 6% of patients experienced DKA (5,6).

IN WHOM HAS SGLT-2 INHIBITOR–ASSOCIATED DKA OCCURRED?

The consensus group reviewed over 80 DKA cases from the literature (3,9,11,17-20), including those involving SGLT-2 inhibition and cases occurring before these agents were available. Conference participants from clinical practice and industry also presented detailed case reports of SGLT-2 inhibitor–associated DKA. In patients taking SGLT-2 inhibitors, DKA occurred most often in insulin-deficient individuals, including those with longstanding T2D, T1D, or LADA. In the case series from the canagliflozin clinical trials, 6 of 12 patients had low C-peptide levels (<0.51 ng/mL) and/or were positive for GAD65 antibodies, and in the American case series that prompted the FDA safety warning, 7 of 9 patients had T1D (3).

Blood glucose levels were not documented for many cases. The lowest recorded value was 90 mg/dL, and 13 cases were associated with blood glucose <180 mg/dL. However, the majority of recorded values were ≥250 mg/dL (3,11,17-20). Patients otherwise had classic signs and symptoms of DKA (Table 1), including pH, bicarbonate, and urine ketones within expected ranges. Metabolic stress was the unifying theme among the cases; nearly all involved surgery, injury, acute illness, exercise, or severely reduced carbohydrate intake.

**WHICH PATHOPHYSIOLOGIC FACTORS CONTRIBUTE TO SGLT-2 INHIBITOR–ASSOCIATED DKA?**

Ketones such as acetoacetate and β-hydroxybutyrate are acidic alternate fuel molecules produced in the liver through the oxidation of fatty acids when dietary carbohydrates are in short supply. Ketones can be metabolized for energy by cardiac and skeletal muscle, the intestine, kidney, and the brain when sufficient glucose is not readily available, and they are excreted in the urine and through the lungs as acetone. When ketone production exceeds clearance, ketoacidosis may occur (21). DKA results from a combination of glucagon elevations, which promote a shift to fat metabolism, and insulin deficiency that may manifest as either an absolute insulin deficiency or a relative deficiency coupled with severe insulin resistance. Hyperglycemia occurs when the lack of insulin and increased glucagon stimulate glycolysis and gluconeogenesis in the liver, whereas insu-

<table>
<thead>
<tr>
<th>Table 1</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Classic signs and symptoms of DKA</strong></td>
</tr>
<tr>
<td>Polyuria</td>
</tr>
<tr>
<td>Polydipsia</td>
</tr>
<tr>
<td>Nausea, vomiting, abdominal pain</td>
</tr>
<tr>
<td>Visual disturbance</td>
</tr>
<tr>
<td>Lethargy, altered sensorium</td>
</tr>
<tr>
<td>Tachycardia, tachypnea</td>
</tr>
<tr>
<td>Kussmaul respirations (dyspnea)</td>
</tr>
<tr>
<td>Acetone smell to breath</td>
</tr>
</tbody>
</table>

Abbreviation: DKA = diabetic ketoacidosis.
lin deficiency, insulin resistance exacerbated by lipolysis, and elevated counterregulatory hormones act in concert to reduce glucose utilization in peripheral tissues. Reduced insulin action coupled with increased glucagon and free fatty acid (FFA) levels promote β-oxidation and hepatic ketogenesis and possibly decreasing ketone utilization in other tissues (8,22). External factors that can precipitate DKA include surgery, infections, sepsis, alcohol, severe injury, hypovolemia, pancreatitis, and severe metabolic stress–related conditions such as myocardial infarction or marathon running (8,22,23).

Changes in diet, notably decreased carbohydrate intake, shifts metabolism to utilization of fat for energy, which promotes ketone production and may contribute to eventual development of DKA under stressful conditions. Very-low-carbohydrate and ketogenic diets (e.g., the Atkins diet) deprive the body of glucose, and the resulting ketosis may develop into ketoacidosis when conditions favor an excessive increase in counterregulatory hormones and the glucagon to insulin ratio (7,19,24-26), such as during severe metabolic stress and (relative) insulin deficiency. Reduced carbohydrate intake was the common factor in a 1973 case series describing 37 T1D patients with “euglycemic” DKA (9). Counterregulatory hormones, including catecholamines, cortisol, and growth hormone—which may be increased by severe stress such as hypovolemia or hypotension—also promote lipolysis and may increase ketone metabolism (27-31). In the setting of insulin deficiency, elevated glucagon also stimulates ketogenesis through promotion of lipolysis in adipocytes and stimulation of β-oxidation of FFA in the liver (31). People with diabetes are typically already more prone to ketosis compared to healthy individuals, perhaps because they may have dopamine deficiency in the brain and central nervous system, which may unleash sympathetic control of glycolysis, lipolysis, neoglucogenesis, and ketogenesis (32).

The kidney plays a central role in conservation of both glucose and ketones, particularly in the fasting state (33,34). During starvation, renal re-absorption of ketones increases with blood concentrations, with no apparent excretion threshold, but renal utilization of ketone bodies is reduced (34,35). By lowering the renal glucose excretion threshold, SGLT-2 inhibition may mimic starvation conditions and cause an increase in ketone production and renal re-absorption (36-40). These findings suggest that ketonuria may be an insensitive biomarker for hyperketonemia and should not be used to diagnose DKA. Similarly, analyses have shown no correlation between plasma glucose and serum bicarbonate values in DKA, in general and specifically during SGLT-2 inhibitor use (41,42).

Proposed causative factors for DKA with lower-than-anticipated glucose levels include partial treatment of DKA, fasting, carbohydrate avoidance, dehydration, alcohol intake, and persistent glycosuria (7,11). “Euglycemic” DKA was first described as being associated with blood glucose values <300 mg/dL (9), and later, a 2009 American Diabetes Association consensus on DKA defined it as glucose level <250 mg/dL (8). However, although blood glucose <140 mg/dL (the postmeal upper limit of normal) has been occasionally reported, the vast majority of so-called euglycemic DKA involves glucose levels above the defined threshold. Therefore, AACE/ACE considers euglycemic DKA a misleading term and instead recommends use of “DKA with lower-than-anticipated glucose levels.”

### WHICH SIGNS AND SYMPTOMS ARE DIAGNOSTIC OF DKA IN PATIENTS TAKING AN SGLT-2 INHIBITOR?

Table 1 lists classic signs and symptoms of DKA, and Table 2 shows recommended diagnostic criteria. Patients with any form of diabetes who have abdominal pain, nausea, vomiting, fatigue, and/or dyspnea should be evaluated for DKA. Because SGLT-2 inhibitors lower the threshold for glucose excretion, normal or modestly elevated blood glucose does not exclude the diagnosis of DKA during SGLT-2 inhibitor use.

Ketonuria and elevated bicarbonate may be suggestive of DKA, but evidence suggests these measures may be inaccurate (36-42). Instead, the diagnosis should be confirmed with direct measurement of β-hydroxybutyrate in blood and arterial pH (Table 2).

### HOW SHOULD DKA ASSOCIATED WITH SGLT-2 INHIBITORS BE MANAGED?

Once the diagnosis is suspected, the SGLT-2 inhibitor should be stopped immediately and the DKA protocol initiated, including fluids, insulin, and other standard interventions as described elsewhere (8).

<table>
<thead>
<tr>
<th>Table 2: Diagnostic Criteria for DKA</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Parameter</strong></td>
</tr>
<tr>
<td>Arterial pH</td>
</tr>
<tr>
<td>β-Hydroxybutyrate</td>
</tr>
<tr>
<td>Serum ketone</td>
</tr>
<tr>
<td>Anion gap</td>
</tr>
<tr>
<td>Mental status</td>
</tr>
</tbody>
</table>

Abbreviation: DKA = diabetic ketoacidosis.

*a*Nitroprusside reaction method.

*b*Anion gap: (Na⁺) − [Cl⁻ + HCO₃⁻] (mEq/L).
HOW SHOULD DKA BE PREVENTED?

Canagliflozin, dapagliflozin, and empagliflozin have similar half-lives, of approximately 13 hours (10). Because of prolonged action on SGLT-2 transporters, these agents should be stopped at least 24 hours before scheduled surgery or other planned activities that might precipitate DKA, such as invasive procedures or extreme physical activity (e.g., running a marathon). For patients with diabetes undergoing emergency surgery or a sudden external severe stress event, the drug should be stopped immediately and, if DKA develops, management with intravenous insulin and glucose considered along with monitoring of anion gap, serum β-hydroxybutyrate, and arterial pH.

Routine measurement of urine ketones is not recommended during use of SGLT-2 inhibitors in T2D because urine ketone measurement can be misleading. Measurement of blood ketones is preferred for diagnosis and monitoring of DKA (Table 2).

Patients taking SGLT-2 inhibitors should avoid excess alcohol intake and very-low-carbohydrate/ketogenic diets.

SHOULD SGLT-2 INHIBITORS BE USED IN PATIENTS WITH T1D?

SGLT-2 inhibitors are not approved for use in T1D, but clinical trials investigating their efficacy and safety in this population are underway. As yet, few data are available to assess the risk of DKA. In an 18-week, phase 2 canagliflozin study involving 351 patients, ketone-related adverse events (including DKA) occurred among 5.1 and 9.4% of T1D patients receiving canagliflozin 100 and 300 mg, respectively, whereas DKA itself occurred among 4.3 and 6.0% of patients, respectively. No ketone-related events occurred in placebo-treated patients (5). No cases of DKA were reported during a 2-week proof of concept study or in a 24-week, open-label study of dapagliflozin in T1D (6,43). In an 8-week, single-arm, open-label study of empagliflozin, 2 patients experienced DKA after insulin pump failure (44), but no cases of DKA occurred during a 4-week, placebo-controlled empagliflozin study (45). Finally, in a 29-day, placebo-controlled study of sotagliflozin, an investigational dual SGLT-1/2 inhibitor, DKA occurred in 2 sotagliflozin-treated patients after insulin pump malfunctions (46).

AACE/ACE recommends continued study of SGLT-2 inhibitors in patients with T1D based on results to date, which suggest addition of an SGLT-2 inhibitor to insulin may enhance glycemic control without increasing the risk of hypoglycemia or weight gain (5,6,43-45). However, in light of the possibility that SGLT-2 inhibition may increase the risk of DKA in T1D, investigators should consider the following when designing future T1D trials:

- Use of lower SGLT-2 inhibitor doses
- Adjustment of insulin doses based on individual response rather than standardized reductions in insulin dose when starting SGLT-2 inhibitor therapy
- Maintenance of current carbohydrate intake

Clinicians should consider applying these recommendations if prescribing SGLT-2 inhibitors off-label to patients with T1D and also when using SGLT-2 inhibitors in combination with insulin to treat T2D.

CONCLUSION

The incidence of DKA in T2D treated with SGLT-2 inhibitors does not appear to exceed the low levels occurring in the general diabetes population. Further study of the mechanisms behind the metabolic effects of SGLT-2 inhibitors is needed to better define the risk of DKA with these agents. Nevertheless, the risk to benefit ratio overwhelmingly favors continued use of SGLT-2 inhibitors in T2D, with no changes in current recommendations. This class has proven benefits in terms of hemoglobin A1C reduction, weight control, and low risk of hypoglycemia (10,47). Because DKA diagnosis is often missed or delayed when patients present with atypical or misleading laboratory values, greater healthcare professional education efforts that focus on the proper diagnosis and treatment of DKA with SGLT-2 inhibitor use, and perhaps other antihyperglycemic agents, are needed.

Comment: After the AACE/ACE consensus meeting concluded, the FDA added a precaution regarding the potential risk of DKA regardless of glucose level with SGLT-2 inhibitors (48-50). They suggested to evaluate affected patients and consider risk factors for ketoacidosis. Patients taking an SGLT-2 inhibitor may require monitoring and temporary discontinuation of the drug in clinical situations known to predispose to ketoacidosis. The EMA issued similar precautionary language, recommending that clinicians consider the possibility of ketoacidosis in patients taking SGLT-2 inhibitors who have symptoms consistent with the condition, even if blood sugar levels are not high. The EMA also asserted that the benefits of SGLT-2 inhibitor therapy outweigh the risks (51).

ACKNOWLEDGMENT

Amanda M. Justice provided medical writing and editorial support funded by AACE.

DISCLOSURE

Dr. Yehuda Handelsman has served as a consultant and/or speaker for Amarin, Amgen, Amylin, Boehringer Ingelheim, Gilead, GlaxoSmithKline, Halozyme, Janssen, Merck, NovoNordisk, Sanofi, and Vivus. He has received
research grants from Amgen, Boehringer Ingelheim, GlaxoSmithKline, Gilead, Intarcia, Lexicon, Merck, NovoNordisk, Sanofi, and Takeda.

**Dr. Robert R. Henry** has served as a consultant for Alere, AstraZeneca, Boehringer Ingelheim, Ionis, Johnson & Johnson/Janssen, and NovoNordisk. He has received research grants from Hitachi, Johnson & Johnson/Janssen, Sanofi Aventis, and ViaCyte.

**Dr. Zachary T. Bloomgarden** has served as a speaker or consultant for BMS/AstraZeneca, Boehringer Ingelheim, Johnson & Johnson, Merck, Novartis, Novo Nordisk, and Santarus. He owns stock in Abbott, Amgen, Covidien, Hospira, Novartis, Pfizer, Roche, St Jude, and Zoetis.

**Dr. Sam Dagogo-Jack** has served as a consultant for AstraZeneca, Boehringer Ingelheim, Janssen, Merck, and Novo Nordisk. He has received research grants from AstraZeneca, Boehringer Ingelheim, and Novo Nordisk.

**Dr. Ralph A. DeFronzo** has served on advisory boards for AstraZeneca, Boehringer Ingelheim, and Novo Nordisk. He has received research grants from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, and Takeda.

**Dr. Daniel Einhorn** has served as a consultant and/or speaker for BMS-AZ-Amylin, Eli Lilly, Freedom-Meditech, Glylysens, Halozyme, Janssen, and NovoNordisk. He has received research grants from AstraZeneca, Eli Lilly, Janssen, Mannkind, Sanofi, and Takeda.

**Dr. Ele Ferrannini** has served on advisory boards for Boehringer Ingelheim, Eli Lilly & Co, GlaxoSmithKline, Janssen, MSD, Sanofi, and Takeda. He has research grants from Boehringer Ingelheim and Eli Lilly & Co.

**Dr. Vivian A. Fonseca** has served as a consultant and/or speaker for Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Novo-Nordisk, Sanofi-Aventis, Pamlabs, and Takeda. His institution has received research grant support from Asahi Kasei, Eli Lilly, Halozyme, Novo-Nordisk, Pamlabs, Reata, and Sanofi-Aventis.

**Dr. Alan J. Garber** has served as a consultant for Novo Nordisk.

**Dr. George Grunberger** has served as a consultant and/or speaker for AstraZeneca, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Janssen, Novo Nordisk, and Sanofi. He has received research support from AstraZeneca, Eli Lilly, Lexicon, Medtronic, Merck, and Novo Nordisk.

**Dr. Derek LeRoith** has served as a consultant for AstraZeneca, BMS/AstraZeneca, Janssen, and Sanofi.

**Dr. Guillermo E. Umpierrez** has served as a consultant for Boehringer Ingelheim, Glytec, Merck Novo Nordisk, Regeneron, and Sanofi. He has received research grants from AstraZeneca, Boehringer Ingelheim, Merck, Novo Nordisk, and Regeneron.

**Dr. Matthew R. Weir** has served as a scientific advisor for AstraZeneca, Janssen, Lilly/BI, and Lexicon.

**Amanda M. Justice** has received consulting fees from Asahi Kasei and Lexicon.

---

**APPENDIX**

The Consensus statement was based on a 2-day international experts’ workshop: AACE/ACE Scientific and Clinical Review: Association of SGLT-2 Inhibitors and DKA

**Chairs:** Yehuda Handelsman, MD, FACP, FNLA, FACE & Robert R. Henry, MD, FACE

**Writing Committee:** Zachary T. Bloomgarden, MD, MACE; Sam Dagogo-Jack, MD, DM, FRCP, FACE; Ralph A. DeFronzo, MD, BMS, MS, BS; Daniel Einhorn, MD, FACP, FACE; Ele Ferrannini, MD; Vivian A. Fonseca, MD, FACE; Alan J. Garber, MD, PhD, FACE; George Grunberger, MD, FACP, FACE; Derek LeRoith, MD, PhD, FACE; Matthew R. Weir, MD

The writing committee, AACE, and ACE are grateful to the presenters for their expert contribution to the consensus.

**Agenda**

<table>
<thead>
<tr>
<th>Topics</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Normal Physiology</strong></td>
<td></td>
</tr>
<tr>
<td>Whole Body Energy Balance – Focus on the Brain</td>
<td>Aaron Vinik, MD, PhD, FCP, MACP, FACE</td>
</tr>
<tr>
<td>Carbohydrate Metabolism: The Importance of Nutrient Sensing</td>
<td>W. Timothy Garvey, MD</td>
</tr>
<tr>
<td>Regulation of Adipose Tissue Lipolysis and Its Relationship with Ketogenesis</td>
<td>John Miles, MD, FACE</td>
</tr>
<tr>
<td>Glucagon Therapeutics, New Biology of Diabetes</td>
<td>Roger Unger, MD</td>
</tr>
<tr>
<td><strong>Pathophysiology</strong></td>
<td></td>
</tr>
<tr>
<td>SGLT-2 Inhibitors and Ketoadidosis: Learnings from the Scientific Literature</td>
<td>Simeon I. Taylor, MD, PhD</td>
</tr>
<tr>
<td>Ketogenesis, Ketosis, and Ketoadidosis</td>
<td>Richard E. Prattley, MD</td>
</tr>
<tr>
<td>The Role of the Kidneys in the Clearance or Re-absorption of Ketone Bodies</td>
<td>Matthew Weir, MD</td>
</tr>
</tbody>
</table>
Epidemiology

SGLT-2 Inhibitors and DKA: The Clinical Stories
George Grunberger, MD, FACP, FACE

Personal Cases
Sam Dagogo-Jack, MD, DM, FRCP, FACE

Background Prevalence of DKA in T2D in Denmark Prior to the SGLT-2 Inhibitors
John Nolan, FRCP, FRCP(ED)

SGLT-2 Inhibitors Treatment in Type 1 Diabetes
Paresh Dandona, MBBS, DPhil, FRCP, FACP, FACC

Regulatory

The European Experience of SGLT-2 Inhibitors and Diabetic Ketoacidosis
Henning Beck-Nielsen, MD, DMSc

Town Hall Meeting

Sustained Response of SGLT-2 Inhibitors on the Kidney
David Polidori, PhD

AstraZeneca Dapagliflozin and DKA Cases: Throughout the Clinical Development & Post Marketing Reports
Nayyar Iqbal, MD, MSCE, FACE

Case Study: Patient with SGLT-2 Inhibitor–Related DKA
Sandra Williams, MD

The Boehringer Ingelheim Available Experience
Thomas Seck, MD

The Public Perspective
Emily Regier, BS

The Lexicon Experience: Type 1 Diabetes
Paul Strumph, MD, FACE

Type 2 Diabetes Patient Profile: DKA After SGLT-2 Inhibitors and Ways to Prevent DKA
Lance Sloan, MD, FACE

Cases, DKA, and Concepts I

DKA in Type 2 Diabetes: Canagliflozin Clinical Program
Daniel Einhorn, MD, FACP, FACE

Ketoacidosis in Canagliflozin: Phase 2 Trial of Type 1 Diabetes
Robert Henry, MD, FACE

Update on DKA in Type 1 Diabetes with SGLT-2 Inhibitors
Anne Peters, MD

Cases, DKA, and Concepts II

SGLT-2 Inhibitors and Ketosis
Ele Ferrannini, MD

The Pathophysiology of DKA in Patients with Diabetes on SGLT-2 Inhibitors
Ralph A. DeFronzo, MD, BMS, MS, BS

Common Features and Contributing Characteristics of DKA in Patients on SGLT-2 Inhibitors
Jaime Davidson, MD, FACP, MACE

Panel & Open Discussion: Clinical Implications and Recommendations for Practice
Moderators: Robert Henry, MD, FACE, and Yehuda Handelsman, MD, FACP, FACE, FNLA, Chair

REFERENCES


48. **Jardiance (empagliflozin) prescribing information.** Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; 2015.

49. **Farxiga (dapagliflozin) prescribing information.** Princeton, NJ: Bristol-Myers Squibb Company; 2015.

50. **Invokana (canagliflozin) prescribing information.** Titusville, NJ: Janssen Pharmaceuticals Inc; 2015.